Universe Pharma expands elderly care with $10.75M patent acquisition

Universe Pharmaceuticals (UPC) said it will acquire Best Praise for $10.75 million in shares, adding five patents in China focused on elderly healthcare research and development.

The deal targets China's aging population. The government has prioritized geriatric care, and UPC is positioning itself in that segment with the added patent portfolio. The specific therapies covered were not disclosed.

UPC is paying with stock. The number of shares issued will depend on the closing price, giving existing shareholders a dilution risk. The company did not say how many shares would be created.

Best Praise brings R&D capabilities in age-related conditions. UPC expects the combination to strengthen its pipeline in a growing market. China's elderly demographic is expanding, and policy support for senior-care products has risen in recent years.

The transaction is expected to close in the second half of the year, pending regulatory approvals.